.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Mallinckrodt
US Department of Justice
Medtronic
Dow
Teva
Merck
Fish and Richardson
Cipla
Chubb

Generated: September 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Pharmaceutical compositions having desirable bioavailability
Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
Inventor(s): Kabra; Bhagwati P. (Euless, TX), Carreras; Nuria (Barcelona, ES), Cuchi; Monica (Barcelona, ES), Galan; Francisco Javier (Teia, ES), Mridvika; (Barcelona, ES), Puig; Elena Gonzalez (Barcelona, ES), Jimenez; Nuria (Barcelona, ES), Martinez; Carmen (Barcelona, ES)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:13/252,255
Patent Claims: 1. A pharmaceutical composition, comprising: an ophthalmic pharmaceutical vehicle suitable for topical application to an eye of a human; an amount of prostaglandin suitable for reducing intraocular pressure of the eye; and surfactant at a relatively low concentration, the concentration being sufficient for providing a high degree of bioavailability of the therapeutic agent, wherein: i. the amount of surfactant is below 0.4 w/v % of the composition; ii. the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil; and iii. the ethoxylated and/or hydrogenated vegetable oil is the only surfactant in the composition; iv. the composition is substantially free of any benzalkonium chloride; and v. the pharmaceutical vehicle includes water.

2. A composition as in claim 1 further comprising a carbonic anhydrase inhibitor wherein the surfactant acts a wetting agent for the carbonic anhydrase inhibitor.

3. A composition as in claim 1 wherein an area under a concentration/time curve when determined for the pharmaceutical composition of the present invention as applied to a biological target is at least 200% relative to a area under a concentration/time curve when determined for a control composition as applied to the biological target, the control composition being substantially identical to the pharmaceutical composition with the exception that the concentration of surfactant is at least doubled and wherein the biological target is eyes of rabbits and concentrations for the concentration/time curve are based upon measurements of prostaglandin in the aqueous humor of the eye of the rabbits.

4. A composition as in claim 1 wherein the prostaglandin is travoprost.

5. A composition as in claim 1 wherein the surfactant is a castor oil.

6. A composition as in claim 1 wherein the surfactant is Polyoxyl 40 Hydrogenated castor oil.

7. A composition as in claim 1 wherein the surfactant is less than 0.3 w/v % of the composition.

8. A composition as in claim 1 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both.

9. A composition as in claim 1 wherein the composition is free of any chlorine containing preservation agents.

10. A composition as in claim 1 wherein the prostaglandin is dissolved in aqueous solution with the assistance of the surfactant.

11. A pharmaceutical composition, comprising: an ophthalmic pharmaceutical vehicle suitable for topical application to an eye of a human; an amount of prostaglandin suitable for reducing intraocular pressure of the eye; and surfactant at a relatively low concentration, the concentration being sufficient for providing a high degree of bioavailability of the therapeutic agent, wherein: i. the amount of surfactant is below 0.3 w/v % of the composition; ii. the surfactant is entirely ethoxylated and/or hydrogenated vegetable oil; iii. the ethoxylated and/or hydrogenated vegetable oil is the only surfactant in the composition; iv. the prostaglandin is travoprost; v. the pharmaceutical vehicle includes water; and vi. the composition is substantially free of any benzalkonium chloride.

12. A composition as in claim 11 wherein the surfactant is Polyoxyl 40 Hydrogenated castor oil.

13. A composition as in claim 11 wherein the surfactant is less than 0.3 w/v % of the composition.

14. A composition as in claim 12 wherein the surfactant is less than 0.3 w/v % of the composition.

15. A composition as in claim 11 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both.

16. A composition as in claim 1 wherein the ophthalmic pharmaceutical vehicle includes a preservative system comprised of a borate, a polyol or both.

17. A composition as in claim 11 wherein the ophthalmic pharmaceutical vehicle includes a preservative system comprised of a borate, a polyol or both.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
UBS
Fuji
Teva
Dow
Chinese Patent Office
Colorcon
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot